Unknown PHASE1 INTERVENTIONAL 1-arm NCT02843321

Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination (CYNTAX)

Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination to Enhance Infection-Specific Immune Reconstitution Post-Allogeneic Stem Cell Transplantation

Sponsor: University of Sydney

Conditions Complication of Transplant

Interventions T-cell infusion, influenza vaccination

Updated 6 times since 2017 Last updated: Nov 21, 2016 Started: Aug 31, 2012 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02843321, this PHASE1 trial focuses on Complication of Transplant and remains ongoing. Sponsored by University of Sydney, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Dec 2018 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status
Jun 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Sydney

Data source: University of Sydney

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Westmead, Sydney, Australia